First Patient Dosed in Proof-of-concept Study of CS1001 Plus Stivarga for Advanced Solid Tumors
News
CStone Pharmaceuticals has dosed the first patient in a clinical trial designed to evaluate CS1001, the company’s experimental PD-L1 inhibitor, in combination with Bayer’s Stivarga (regorafenib), for the treatment of advanced ... Read more